Invesco Ltd. 2seventy Bio, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 100,369 shares of TSVT stock, worth $327,202. This represents 0.0% of its overall portfolio holdings.

Number of Shares

100,369

Previous 100,882 0.51%

Holding current value

$327,202

Previous $388,000 21.91%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.85 - $5.05 $1,975 - $2,590	-513 Reduced 0.51%	100,369 $473,000
Q2 2024 Aug 13, 2024	SELL	$3.6 - $5.79 $3,214 - $5,170	-893 Reduced 0.88%	100,882 $388,000
Q1 2024 May 14, 2024	BUY	$3.09 - $6.0 $169,016 - $328,188	54,698 Added 116.19%	101,775 $544,000
Q4 2023 Feb 12, 2024	BUY	$1.57 - $4.58 $4,141 - $12,082	2,638 Added 5.94%	47,077 $201,000
Q3 2023 Nov 13, 2023	BUY	$3.14 - $11.2 $1,862 - $6,641	593 Added 1.35%	44,439 $174,000
Q2 2023 Aug 11, 2023	SELL	$8.45 - $12.48 $3,363 - $4,967	-398 Reduced 0.9%	43,846 $443,000
Q1 2023 May 12, 2023	BUY	$9.21 - $14.98 $110,446 - $179,640	11,992 Added 37.18%	44,244 $451,000
Q4 2022 Feb 13, 2023	BUY	$8.57 - $17.0 $5,424 - $10,761	633 Added 2.0%	32,252 $302,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $17.54 $14,783 - $20,644	-1,177 Reduced 3.59%	31,619 $460,000
Q2 2022 Aug 15, 2022	BUY	$10.55 - $18.81 $73,480 - $131,011	6,965 Added 26.96%	32,796 $434,000
Q1 2022 May 16, 2022	BUY	$11.67 - $26.72 $12,148 - $27,815	1,041 Added 4.2%	25,831 $440,000
Q4 2021 Feb 14, 2022	BUY	$13.77 - $42.56 $341,358 - $1.06 Million	24,790 New	24,790 $636,000

Others Institutions Holding TSVT

# of Institutions

126

Shares Held

45.6M

Call Options Held

122K

Put Options Held

19.8K

View Full List

About 2seventy bio, Inc.

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $123M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

More about TSVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account